Biohaven Stock’s Wild Ride: Big Drops, Big Hopes as FDA Verdict Nears
In summary, Biohaven’s stock is a tale of high stakes in biotech. Recent price swings underscore the uncertainty, but also the potential reward if Biohaven’s bets pay off. With an FDA verdict looming and multiple shots on goal in its
